P800 Treatment patterns for biologics in ulcerative colitis and Crohn’s disease: A Danish Nationwide Register Study from 2003 to 2015
S. Alulis1, K. Vadstrup2, A. Borsi3, A. Nielsen4, T. Rikke Jørgensen5, N. Qvist6, P. Munkholm7
1Janssen-Cilag, External Affairs, Birkerød, Denmark, 2Janssen-Cilag, Medical Affairs, Birkerød, Denmark, 3Janssen-Cilag, External Affairs, High Wycombe, UK, 4Incentive, Evidence Generation, Holte, Denmark, 5LEO Pharma, Global Public Affairs, Copenhagen, Denmark, 6Odense University Hospital, Surgical Department A and IBD Care, Odense, Denmark, 7North Zealand University Hospital, Gastroenterology Department, Frederikssund, Denmark
Background
The choice of biological treatment for Crohn’s disease (CD) and Ulcerative Colitis (UC) depends on disease severity and possible other factors. Patients with moderate to severe disease should be prescribed biologic response modifiers (biologics), according to guidelines. This study aims to explore the treatment patterns of patients diagnosed with CD and UC.
Methods
This national register study included patients diagnosed between 2003 and 2015, identified in the Danish National Patient Registry (NPR). Biologic therapies available during the study period were infliximab, adalimumab, vedolizumab and golimumab. The share of patients initiating and receiving biologic treatment in each year was calculated. Additionally, the time from IBD diagnosis to first biologic treatment and time between treatments were calculated.
Results
Among 10,302 CD patients and 22,144 UC patients, 28.5% of CD patients and 11.3% of UC patients received treatment with biologics during the study period, with an increasing number of patients initiating treatment with biologics for each successive year. 46% of CD and 45% of UC patients in the study population received their first biologic treatment within the first year after IBD diagnosis. 57–68% of CD and UC patients started treatment with their second line biologic within two months of the last treatment with their first line.
Conclusion
The number of patients initiating biologic treatments after diagnosis increased throughout the study period. Approximately half of patients diagnosed with CD and UC are receiving biologic treatments within the first year after diagnosis.